Skip to main content

Lartruvo Side Effects

Generic name: olaratumab

Medically reviewed by Last updated on Sep 27, 2023.

Note: This document contains side effect information about olaratumab. Some dosage forms listed on this page may not apply to the brand name Lartruvo.

Applies to olaratumab: intravenous solution.

Serious side effects of Lartruvo

Along with its needed effects, olaratumab (the active ingredient contained in Lartruvo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking olaratumab:

More common

Other side effects of Lartruvo

Some side effects of olaratumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to olaratumab: intravenous solution.


The most common (20% or greater) adverse reactions of this drug plus doxorubicin are nausea, fatigue, musculoskeletal pain, mucositis, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy, and headache.[Ref]


Very common (10% or more): Alopecia (up to 52%)[Ref]


Very common (10% or more): Nausea (up to 73%), mucositis (up to 53%), vomiting (up to 45%), diarrhea (up to 34%), abdominal pain upper/lower (up to 23%)


Very common (10% or more): Lymphopenia (up to 77%), neutropenia (up to 65%), thrombocytopenia (up to 63%), elevated activated partial thromboplastin time (aPTT) (33%)[Ref]


Common (1% to 10%): Treatment emergent immunogenicity[Ref]


Very common (10% or more): Hyperglycemia (up to 52%), appetite decreased (up to 31%), hypokalemia (up to 21%), hypophosphatemia (up to 21%), alkaline phosphatase increased (16%), hypomagnesemia (up to 16%)[Ref]


Very common (10% or more): Musculoskeletal pain (i.e., arthralgia, back pain, bone pain, flank pain, groin pain, musculoskeletal chest pain, myalgia, muscle spasms, neck pain, pain in extremity) (up to 64%)[Ref]

Nervous system

Very common (10% or more): Neuropathy (up to 22%), headache (up to 20%)[Ref]


Very common (10% or more): Dry eyes (up to 11%)[Ref]


Very common (10% or more): Fatigue/asthenia (up to 69%), flushing, fever/chills (up to 14%)[Ref]


Very common (10% or more): Anxiety (up to 11%)[Ref]


Very common (10% or more): Shortness of breath, bronchospasm[Ref]


Frequency not reported: Anaphylactic shock[Ref]


Frequency not reported: Severe hypotension, cardiac arrest[Ref]

Frequently asked questions


1. Product Information. Lartruvo (olaratumab). Lilly, Eli and Company. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.